Skip to content
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Clinical Trials
MT-0169
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease